parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in astrocytes (96 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 167	0.91
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 13400

POU3F2 in dopamine neurons, braak-0.29 (p 0.457) → +0.33 (p 0.387)receipt 13408
POU3F2 in astrocytes, braak-0.15 (p 0.702) → +0.42 (p 0.258)receipt 13407

receipt 13408: POU3F2 in dopamine neurons, braak

power: full sample +0.00 (p 0.990, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.794, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.10 (p 0.696, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.16, sign flips 12; without severely affected donors +0.00 (p 0.990, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for POU3F2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13407: POU3F2 in astrocytes, braak

power: full sample +0.03 (p 0.915, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.915, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.26 (p 0.306, n 18). could be the mix.
skeptic: leave-one-out range -0.08 to +0.16, sign flips 7; without severely affected donors +0.03 (p 0.915, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for POU3F2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts